SBT 16th Annual Meeting

Oral Abstracts

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

Therapeutic and Specific Antitumor Immunity Induced by IL12 and IL18 in Fibroblasts and DCs: Preclinical Studies and Application to Patients

IL-15: Relevance in Biology and Disease

The Laboratory and Clinical Biology of Cancer Treatment with Tumor Reactive mAb Linked to IL2

Preclinical and Clinical Investigation of IL-12/Pulse IL-2

Phase I Trial of Twice-Weekly IV rhIL-12 Plus Low-Dose SC IL-2 in Patients with Melanoma and Renal Cell Cancer

IL-7: Emerging role in immunorestoration and vaccination

Tumor Vaccination with Interleukin-12 and Granulocyte Macrophage-Colony Stimulating Factor-Encapsulated Microspheres: Co-induction of Innate and Adaptive Immunity Promotes Cure of Disseminated Disease

A Randomized Phase III Trial of High-Dose Interleukin-2 (HD IL2) versus Subcutaneous (SC) IL2/Interferon (IFN) in Patients with Metastatic Renal Cell Carcinoma (RCC)

Title: Phenotypic Diversity of Endothelial Cells is Defined by the Organ Microenvironment

The Imaging of Angiogenesis

Molecular Determinants of the Angiogenic Switch and Tumor Progression

Endothelial Cell Gene Expression Profiling

In vivo tumor imaging using near infrared labeled Endostatin

Peptide-Targeting IL-12 to avb3 Integrin Mediates Potent Antiangiogenic Activity

Signal and transcriptional activation of proinflammatory and proangiogenic factor expression by cancer cells as a target for biological therapy

Preclinical Strategies to Improve Dendritic Cell-Based Tumor Vaccines

Dendritic cells as vectors and targets for therapy

Multi-epitope Peptide Vaccines with GMCSF and IL2: CTL Responses in the Peripheral Blood and in the Sentinel Immunized Node

Immunization of HLA-A2+ Melanoma Patients in the Adjuvant Setting with a Mutated gp100 Peptide (209-2M) Induces Specific T Cell Immune Responses

Transduction of human dendritic cells with a melanoma polyepitope simultaneously primes multiple T-cell responses but ultimately results in immunodominance

Comparative Analysis of Necrotic and Apoptotic Tumor Cells as a Source of Antigen(s) in Dendritic Cell-Based Immunization

Pharmacogenomic Applied to Drug Development

Directed Molecular Evolution of Vaccines and Immunotherapeutics

Approaches for Identifying and Accelerating the Prioritization of all the Potential Target Genes and Therapeutic Proteins in the Genome

Classification and Diagnostic Prediction of Cancers using Gene Expression Profiling and Artificial Neural Networks

Clinical Proteomics: Toward Personalized Molecular Medicine

Ranitidine as adjuvant treatment in colorectal cancer: Influence of blood transfusion and postoperative bacterial infections

Phase I/IB trial of the immunocytokine hu14.18-IL2 in patients with GD2-positive tumors

Prophylactic Antitumor Efficacy of a Combination Therapy With a Xenogeneic Cell Line Producing Flt3-Ligand (FL),Tumor Cell Lysate, and Interleukin-2 in Mice With Syngeneic Colon Cancer

Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats

Intratumoral Expansion of Tumor-Specific B Cells in Invasive Ductal Carcinoma of the Breast

Signaling defects in CD8+CD27-CD45RO- circulating effector cells in patients with cancer


Humanized Anti–HLA-DR Monoclonal Antibody Hu1D10 (Remitogen) for the Treatment of Relapsed Non-Hodgkin’s Lymphoma: A Phase I Trial

Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (anti-CTLA-4) Monoclonal Antibody (MDX-CTLA-4) in Patients with Metastatic Melanoma

Early-Phase Clinical Development of the Immunocytokine EMD 273066 (huKS-IL2): Laboratory and Safety Findings in Patients With Prostate Cancer

Synergistic anti-tumor responses against metastatic cancer using antibodies to CD40 and IL2: coordination of dendritic cell and T cell arms of the immune response

Recurrent Murine Neuroblastomas Increase or Decrease MHC Class I Expression to Respectively Escape NK- or T Cell-Dependent Immunotherapy

Combined Administration of Antibodies to Human Interleukin-8 and Epidermal Growth Factor Receptor Results in Increased Anti-metastatic Effects on Human Breast Carcinoma Xenografts

Repopulating stem cells carrying chemotherapy resistance-inducing genes

Clinical Results of a PSA-Selective, Replication-Competent Adenovirus for the Treatment of Prostate Cancer.

Vaccines for Cancer Treatment: From Mice to Men

Differential impact of local production interleukin-2 and interleukin-12 on initial appearance and long-term progression of B16F10 melanoma in mice

A DNA Vaccine Encoding Genetic Fusions of CEA and GMCSF

Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv

Thalidomide and its Successor Molecules as Agents for Biological Therapy

From Coley’s Toxins to Immunotherapy with CpG DNA Motifs from Bacterial DNA


ANGIOZYME, a synthetic ribozyme targeting the mRNA of VEGFR-1: clinical update

Pharmacokinetics in beagle dogs and cynomologus monkeys, of VNP20009, an attenuated Salmonella typhimurium for the treatment of cancer

A Phase 2 Trial To Evaluate the Rate of Immune Response Using Recombinant Idiotype for Treatment of Follicular Non-Hodgkin’s Lymphoma

Shikonin, a small molecule compound from Chinese herbal medicine with anti-inflammatory and anti-HIV-1 activity, is an inhibitor of multiple chemokine receptors

TRAIL Induced Apoptosis of Human Melanoma is Regulated by Smac/DIABLO Release from Mitochondria

The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated lysis